<table border="1" cellpadding="7" cellspacing="1" width="615" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 4 Drug Interactions: Changes in Pharmacokinetic Parameters for Co-administered Drug in the Presence of Nevirapine (All interaction trials were conducted in HIV-1 positive subjects)</caption>
<tbody>
<tr>
<td valign="top">
<content stylecode="bold">Co-administered Drug</content>
</td>
<td valign="top">
<content stylecode="bold">Dose of Co-administered Drug</content>
</td>
<td valign="top">
<content stylecode="bold">Dose Regimen of nevirapine</content>
</td>
<td valign="top">
<content stylecode="bold">n</content>
</td>
<td colspan="3" valign="top">
<content stylecode="bold">% Change of Co-administered Drug Pharmacokinetic Parameters (90% CI)</content>
</td>
</tr>
<tr>
<td colspan="3" valign="top">
<content stylecode="bold">Antiretrovirals</content>
</td>
<td valign="top"> </td>
<td valign="top">
<content stylecode="bold">AUC</content>
</td>
<td valign="top">C<sub>max</sub>
</td>
<td valign="top">C<sub>min</sub>
</td>
</tr>
<tr>
<td rowspan="2" valign="top">Atazanavir/Ritonavir <sup>a,d</sup>
</td>
<td rowspan="2" valign="top">300/100 mg QD day 4–13, then 400/100 mg QD, day 14–23</td>
<td rowspan="2" valign="top">200 mg BID day 1-23. Subjects were treated with nevirapine prior to trial entry.</td>
<td rowspan="2" valign="top">23</td>
<td valign="top">
<content stylecode="underline">Atazanavir300/100 mg</content>
<br/>↓42<br/>(↓52 to ↓29)</td>
<td valign="top">
<content stylecode="underline">Atazanavir300/100 mg<br/>
</content>↓28<br/>(↓40 to ↓14)</td>
<td valign="top">
<content stylecode="underline">Atazanavir300/100 mg</content>
<br/>↓72<br/>(↓80 to ↓60)</td>
</tr>
<tr>
<td valign="top">
<content stylecode="underline">Atazanavir<br/>400/100 mg<br/>
</content>↓19<br/>(↓35 to ↑­2)</td>
<td valign="top">
<content stylecode="underline">Atazanavir<br/>400/100 mg­<br/>
</content>↑2<br/>(↓15 to ↑­24)</td>
<td valign="top">
<content stylecode="underline">Atazanavir<br/>400/100 mg<br/>
</content>↓59<br/>(↓73 to ↓40)</td>
</tr>
<tr>
<td valign="top">Darunavir/Ritonavir<sup>e</sup>
</td>
<td valign="top">400/100 mg BID</td>
<td valign="top">200 mg BID</td>
<td valign="top">8</td>
<td valign="top">↑­24<br/>(↓3 to ↑57)</td>
<td valign="top">↑­40<br/>(↑14 to ↑73)</td>
<td valign="top">↑­2<br/>(↓21 to↑32 )</td>
</tr>
<tr>
<td valign="top">Didanosine</td>
<td valign="top">100-150 mg BID</td>
<td valign="top">200 mg QD x 14 days; 200 mg BID x 14 days</td>
<td valign="top">18</td>
<td valign="top">
<content stylecode="bold">#</content>
</td>
<td valign="top">
<content stylecode="bold">#</content>
</td>
<td valign="top">§</td>
</tr>
<tr>
<td valign="top">Efavirenz<sup>a</sup>
</td>
<td valign="top">600 mg QD</td>
<td valign="top">200 mg QD x 14 days; 400 mg QD x 14 days</td>
<td valign="top">17</td>
<td valign="top">↓28<br/>(↓34 to ↓14)</td>
<td valign="top">↓12<br/>(↓23 to ↑­1)</td>
<td valign="top">↓32<br/>(↓35 to ↓19)</td>
</tr>
<tr>
<td valign="top">Fosamprenavir</td>
<td valign="top">1400 mg BID</td>
<td valign="top">200 mg BID. Subjects were treated with nevirapine prior to trial entry.</td>
<td valign="top">17</td>
<td valign="top">↓33<br/>(↓45 to ↓20)</td>
<td valign="top">↓25<br/>(↓37 to ↓10)</td>
<td valign="top">↓35<br/>(↓50 to ↓15)</td>
</tr>
<tr>
<td valign="top">Fosamprenavir/Ritonavir</td>
<td valign="top">700/100 mg BID</td>
<td valign="top">200 mg BID. Subjects were treated with nevirapine prior to trial entry</td>
<td valign="top">17</td>
<td valign="top">↓11<br/>(↓23 to ↑­3)</td>
<td valign="top">
<content stylecode="bold">#</content>
</td>
<td valign="top">↓19<br/>(↓32 to ↓4)</td>
</tr>
<tr>
<td valign="top">Indinavir<sup>a</sup>
</td>
<td valign="top">800 mg q8H</td>
<td valign="top">200 mg QD x 14 days; 200 mg BID x 14 days</td>
<td valign="top">19</td>
<td valign="top">↓31<br/>(↓39 to ↓22)</td>
<td valign="top">↓15<br/>(↓24 to ↓4)</td>
<td valign="top">↓44<br/>(↓53 to ↓33)</td>
</tr>
<tr>
<td valign="top">Lopinavir <sup>a, b</sup>
</td>
<td valign="top">300/75 mg/m<sup>2</sup>(lopinavir/ritonavir) <sup>b</sup>
</td>
<td valign="top">7 mg/kg or 4 mg/kg QD x 2 weeks; BID x 1 week</td>
<td valign="top">12, 15 c</td>
<td valign="top">↓22<br/>(↓44 to ↑­9)</td>
<td valign="top">↓14<br/>(↓36 to ↑­16)</td>
<td valign="top">↓55<br/>(↓75 to ↓19)</td>
</tr>
<tr>
<td valign="top">Lopinavir<sup>a</sup>
</td>
<td valign="top">400/100 mg BID (lopinavir/ritonavir)</td>
<td valign="top">200 mg QD x 14 days; 200 mg BID &gt;1 year</td>
<td valign="top">22, 19 c</td>
<td valign="top">↓27<br/>(↓47 to ↓2)</td>
<td valign="top">↓19<br/>(↓38 to ↑­5)</td>
<td valign="top">↓51<br/>(↓72 to ↓26)</td>
</tr>
<tr>
<td valign="top">Maraviroc <sup>f</sup>
</td>
<td valign="top">300 mg SD</td>
<td valign="top">200 mg BID</td>
<td valign="top">8</td>
<td valign="top">↑­1<br/>(↓35 to ↑55)</td>
<td valign="top">↑­54<br/>(↓6 to ↑151)</td>
<td valign="top">#</td>
</tr>
<tr>
<td rowspan="2" valign="top">Nelfinavir<sup>a</sup>
<br/>
<br/>
<sup></sup>
<br/>
<br/>Nelfinavir-M8 metabolite</td>
<td rowspan="2" valign="top">750 mg TID</td>
<td rowspan="2" valign="top">200 mg QD x 14 days; 200 mg BID x 14 days</td>
<td rowspan="2" valign="top">23</td>
<td valign="top">#</td>
<td valign="top">#</td>
<td valign="top">↓32 <br/>(↓50 to ↑­5)</td>
</tr>
<tr>
<td valign="top">↓62<br/>(↓70 to ↓53)</td>
<td valign="top">↓59<br/>(↓68 to ↓48)</td>
<td valign="top">↓66<br/>(↓74 to ↓55)</td>
</tr>
<tr>
<td valign="top">Ritonavir</td>
<td valign="top">600 mg BID</td>
<td valign="top">200 mg QD x 14 days; 200 mg BID x 14 days</td>
<td valign="top">18</td>
<td valign="top">#</td>
<td valign="top">#</td>
<td valign="top">#</td>
</tr>
<tr>
<td valign="top">Stavudine</td>
<td valign="top">30-40 mg BID</td>
<td valign="top">200 mg QD x 14 days; 200 mg BID x 14 days</td>
<td valign="top">22</td>
<td valign="top">#</td>
<td valign="top">#</td>
<td valign="top">§</td>
</tr>
<tr>
<td valign="top">Zalcitabine</td>
<td valign="top">0.125-0.25 mg TID</td>
<td valign="top">200 mg QD x 14 days; 200 mg BID x 14 days</td>
<td valign="top">6</td>
<td valign="top">#</td>
<td valign="top">#</td>
<td valign="top">§</td>
</tr>
<tr>
<td valign="top">Zidovudine</td>
<td valign="top">100-200 mg TID</td>
<td valign="top">200 mg QD x 14 days; 200 mg BID x 14 days</td>
<td valign="top">11</td>
<td valign="top">↓28<br/>(↓40 to ↓4)</td>
<td valign="top">↓30<br/>(↓51 to ↑­14)</td>
<td valign="top">§</td>
</tr>
<tr>
<td colspan="4" valign="top">
<content stylecode="bold">Other Medications</content>
</td>
<td valign="top">
<content stylecode="bold">AUC</content>
</td>
<td valign="top">
<content stylecode="bold">C<sub>max</sub>
</content>
</td>
<td valign="top">
<content stylecode="bold">C<sub>min</sub>
</content>
</td>
</tr>
<tr>
<td rowspan="2" valign="top">Clarithromycin<sup>a</sup>
<br/>
<br/>
<br/>Metabolite 14-OH-clarithromycin</td>
<td rowspan="2" valign="top">500 mg BID</td>
<td rowspan="2" valign="top">200 mg QD x 14 days; 200 mg BID x 14 days</td>
<td rowspan="2" valign="top">15</td>
<td valign="top">↓31<br/>(↓38 to ↓24)</td>
<td valign="top">↓23<br/>(↓31 to ↓14)</td>
<td valign="top">↓56<br/>(↓70 to ↓36)</td>
</tr>
<tr>
<td valign="top">↑­42<br/>(↑16 to ↑73)</td>
<td valign="top">↑­47<br/>(↑21 to ↑­80)</td>
<td valign="top">#</td>
</tr>
<tr>
<td rowspan="2" valign="top">Ethinyl estradiol<sup>a </sup>and Norethindrone<sup>a</sup>
</td>
<td rowspan="2" valign="top">0.035 mg (as Ortho-Novum<sup>®</sup> 1/35)1 mg (as Ortho- Novum<sup>®</sup> 1/35)</td>
<td rowspan="2" valign="top">200 mg QD x 14 days; 200 mg BID x 14 days</td>
<td rowspan="2" valign="top">10</td>
<td valign="top">↓20<br/>(↓33 to ↓3)</td>
<td valign="top">#</td>
<td valign="top">§</td>
</tr>
<tr>
<td valign="top">↓19<br/>(↓30 to ↓7)</td>
<td valign="top">↓16<br/>(↓27 to ↓3)</td>
<td valign="top">§</td>
</tr>
<tr>
<td valign="top">Depomedroxyprogesterone acetate</td>
<td valign="top">150 mg every 3 months</td>
<td valign="top">200 mg QD x 14 days; 200 mg BID x 14 days</td>
<td valign="top">32</td>
<td valign="top">#</td>
<td valign="top">#</td>
<td valign="top">#</td>
</tr>
<tr>
<td valign="top">Fluconazole</td>
<td valign="top">200 mg QD</td>
<td valign="top">200 mg QD x 14 days; 200 mg BID x 14 days</td>
<td valign="top">19</td>
<td valign="top">#</td>
<td valign="top">#</td>
<td valign="top">#</td>
</tr>
<tr>
<td valign="top">Ketoconazole<sup>a</sup>
</td>
<td valign="top">400 mg QD</td>
<td valign="top">200 mg QD x 14 days; 200 mg BID x 14 days</td>
<td valign="top">21</td>
<td valign="top">↓72<br/>(↓80 to ↓60)</td>
<td valign="top">↓44<br/>(↓58 to ↓27)</td>
<td valign="top">§</td>
</tr>
<tr>
<td valign="top">Methadone<sup>a</sup>
</td>
<td valign="top">Individual Subject Dosing</td>
<td valign="top">200 mg QD x 14 days; 200 mg BID ≥7 days</td>
<td valign="top">9</td>
<td colspan="3" valign="top">In a controlled pharmacokinetic trial with 9 subjects receiving chronic methadone to whom steady-state nevirapine therapy was added, the clearance of methadone was increased by 3-fold, resulting in symptoms of withdrawal, requiring dose adjustments in 10 mg segments, in 7 of the 9 subjects. Methadone did not have any effect on nevirapine clearance.</td>
</tr>
<tr>
<td rowspan="2" valign="top">Rifabutin<sup>a</sup>
<br/>
<sup> </sup>
<br/>Metabolite 25-O-desacetyl-rifabutin</td>
<td rowspan="2" valign="top">150 or 300 mg QD</td>
<td rowspan="2" valign="top">200 mg QD x 14 days; 200 mg BID x 14 days</td>
<td rowspan="2" valign="top">19</td>
<td valign="top">↑­17<br/>(↓2 to ↑40)</td>
<td valign="top">↑­28<br/>(↑9 to ↑­51)</td>
<td valign="top">#</td>
</tr>
<tr>
<td valign="top">↑­24<br/>(↓16 to ↑­84)</td>
<td valign="top">↑­29<br/>(↓2 to ↑­68)</td>
<td valign="top">↑­22<br/>(↓14to ↑­74)</td>
</tr>
<tr>
<td valign="top">Rifampin<sup>a</sup>
</td>
<td valign="top">600 mg QD</td>
<td valign="top">200 mg QD x 14 days; 200 mg BID x 14 days</td>
<td valign="top">14</td>
<td valign="top">↑­11<br/>(↓4 to ↑­28)</td>
<td valign="top">#</td>
<td valign="top">§</td>
</tr>
<tr>
<td colspan="7" valign="top">§ = C<sub>min</sub> below detectable level of the assay <br/>↑ = Increase, ↓ = Decrease, #= No Effect <br/>
<sup>a</sup> For information regarding clinical recommendations, see Drug Interactions <linkhtml href="#DRUG_INTERACTIONS">(7)</linkhtml>. <br/>
<sup>b</sup> Pediatric subjects ranging in age from 6 months to 12 years <br/>
<sup>c</sup> Parallel group design; n for nevirapine +lopinavir/ritonavir, n for lopinavir/ritonavir alone. <br/>
<sup>d</sup> Parallel group design; n=23 for atazanavir/ritonavir + nevirapine, n=22 for atazanavir/ritonavir without nevirapine. Changes in atazanavir PK are relative to atazanavir/ritonavir 300/100 mg alone. <br/>
<sup>e</sup> Based on between-trial comparison. <br/>
<sup>f</sup> Based on historical controls.</td>
</tr>
</tbody>
</table>